Orthocell Ltd (OCC)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 0.650 |
|---|---|
| 52-week range | 0.630 – 1.300 |
| Return, 1 month / 3 months | −11.6% / −9.1% |
| Return, 1 year / 3 years | −49.6% / +100.0% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 53.1% |
| Worst drawdown (1 year) | -49.0% |
| Average daily value traded | 0.21M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Orthocell Ltd is an Australian regenerative medicine company based in Perth that develops collagen-based medical devices and cell therapies. Its products are used in the repair of nerves, tendons and cartilage, and include collagen scaffolds and autologous cell treatments for orthopaedic and reconstructive applications. The company works with surgeons and healthcare providers, and its activities span product development, clinical testing and manufacturing of biologic implants for use in human medicine.
On this site Orthocell Ltd appears as a stock on the Australian Securities Exchange (Australia), code OCC, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Orthocell Ltd (OCC) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.650 on 20 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 904 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 49.6% and over the last three months it fell 9.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 42 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.0% | ||
| From 52-week high | -48.6% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.1% | ||
| 6-month return | -25.3% | ||
| 12-month return, skipping the last month | -43.0% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 53.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.0% | ||
| Liquidity | 68 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.21M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −4.4% |
|---|---|
| 1 month | −11.6% |
| 3 months | −9.1% |
| 6 months | −25.3% |
| 1 year | −49.6% |
| 3 years | +100.0% |
| 5 years | +23.8% |
Signals
| 50-day / 200-day average | 0.735 / 0.812 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.034 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.